BusinessGalectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017By Nasdaq OMXDec 4, 2017, 9:00 PM UTC
BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017By Nasdaq OMXNov 13, 2017, 2:01 PM UTC
BusinessGalectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXNov 7, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017By Nasdaq OMXSep 25, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02By Nasdaq OMXSep 12, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Announces Important Milestones towards Completion of NASH CX TrialBy Nasdaq OMXJun 13, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02By Nasdaq OMXApr 25, 2017, 12:02 PM UTC
BusinessGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02By Nasdaq OMXApr 25, 2017, 12:02 PM UTC
